Abstract Search

ea0098c46 | Clinical – Surgery/Applied Pathology | NANETS2023

Peptide receptor radionuclide therapy improves survival in patients who progress after resection of gastroenteropancreatic neuroendocrine tumors

Borbon Luis C. , Sherman Scott K. , Breheny Patrick , Ear Po H. , Menda Yusuf , Chandrasekharan Chandrikha , Bellizzi Andrew M. , O'Dorisio Thomas M. , Dillon Joseph S. , Howe James R

Background: Peptide Receptor Radionuclide Therapy (PRRT) is effective for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) and received FDA approval after demonstrating improved progression-free-survival (PFS) in advanced midgut NETs. We investigated a two-decade experience with PRRT, hypothesizing that PRRT confers PFS and overall-survival (OS) advantages in patients who progress after surgery.Methods: A single-institutional NET database was re...

0 shares

ea0098b15 | Basic Science | NANETS2023

Investigating serotonin metabolism in neuroendocrine cancers

Tow Dane H. , Ridder Maclain , Tran Catherine G. , Borbon Luis C. , Li Guiying , Kaemmer Courtney A. , Abusada Ellen , Harish Mahalingam Aswanth , Sadanandam Anguraj , Chandrasekharan Chandrikha , Dillon Joseph , Spitz Douglas R. , Quelle Dawn E. , H.F. Chan Carlos , Bellizzi Andrew , Howe James R. , Po Hien Ear and

Background: Small bowel neuroendocrine tumors (SBNETs) originate from enterochromaffin cells in the intestine which synthesize and secrete serotonin. Other NETs and other cancers may also produce serotonin but do not store them in vesicles. The rate limiting enzyme of serotonin biosynthesis is tryptophan hydroxylase 1 (Tph1). Patients with high serotonin level could develop carcinoid syndrome, which can be treated with somatostatin analogues and the Tph1 inhibitor telotristat ...

0 shares

Endocrine Abstracts

Peptide receptor radionuclide therapy improves survival in patients who progress after resection of gastroenteropancreatic neuroendocrine tumors

Investigating serotonin metabolism in neuroendocrine cancers

BiosciAbstracts